Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2025 Jan 8

PMID 39770405

Authors

Ming-Cheng Chang

Cheng-Liang Peng

Chun-Tang Chen

Ying-Hsia Shih

Jyun-Hong Chen

Yi-Jou Tai

Ying-Cheng Chiang

Affiliations

Soon will be listed here.

Abstract

Iodine-123 metaiodobenzylguanidine (I-123 MIBG) is a crucial radiopharmaceutical widely used in nuclear medicine for its diagnostic capabilities in both cardiology and oncology. This review aims to present a comprehensive evaluation of the clinical applications of I-123 MIBG, focusing on its use in diagnosing and managing various diseases. In cardiology, I-123 MIBG has proven invaluable in assessing cardiac sympathetic innervation, particularly in patients with heart failure, where it provides prognostic information that guides treatment strategies. In oncology, I-123 MIBG is primarily utilized for imaging neuroendocrine tumors, such as neuroblastoma and pheochromocytoma, where it offers high specificity and sensitivity in the detection of adrenergic tissue. Additionally, its role in neurology, specifically in differentiating between Parkinson's disease, dementia, and Lewy body dementia, has become increasingly significant due to its ability to identify postganglionic sympathetic dysfunction. Despite its established clinical utility, the use of I-123 MIBG is not without limitations, including variability in imaging protocols and interpretation challenges. This review will explore these issues and discuss emerging alternatives, while also highlighting areas where I-123 MIBG continues to be a gold standard. By synthesizing the current research, this article aims to provide a clear understanding of the strengths, limitations, and prospects of I-123 MIBG in clinical practice.

References

Sung C, Lee H, Lee D, Kim Y, Kim J, Lee S . A Prospective Comparative Study of 18 F-FDOPA PET/CT Versus 123 I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2023; 49(1):27-36. PMC: 11805481. DOI: 10.1097/RLU.0000000000004963. View

Bayer M, Kuci Z, Schomig E, Grundemann D, Dittmann H, Handgretinger R . Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells. Nucl Med Biol. 2009; 36(3):287-94. DOI: 10.1016/j.nucmedbio.2008.12.010. View

Verschure D, Veltman C, Manrique A, Somsen G, Koutelou M, Katsikis A . For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging. 2014; 15(9):996-1003. DOI: 10.1093/ehjci/jeu044. View

Henderson E, Kahn J, Corbett J, Jansen D, Pippin J, Kulkarni P . Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988; 78(5 Pt 1):1192-9. DOI: 10.1161/01.cir.78.5.1192. View

Chun I . Optimal Protocol and Clinical Usefulness of I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson's Disease and Dementia with Lewy Body from Non-Parkinson's Diseases. Nucl Med Mol Imaging. 2023; 57(3):145-154. PMC: 10172433. DOI: 10.1007/s13139-023-00790-w. View

Saito S, Nakajima K, Shibutani T, Wakabayashi H, Yoneyama H, Konishi T . Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT. Ann Nucl Cardiol. 2023; 9(1):61-67. PMC: 10696146. DOI: 10.17996/anc.23-00002. View

Somers G, Vanden Houte K, Segers O, Bossuyt A . Iodine-123 MIBG imaging in a generalized pancreatic polypeptide-gastrin-serotonin secreting tumor. Clin Nucl Med. 1988; 13(5):352-5. DOI: 10.1097/00003072-198805000-00012. View

Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A . Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. 2006; 113(1):81-6. DOI: 10.1007/s00401-006-0160-y. View

Ishii K, Kubo A, Kusakabe K, Murata H, Masaki H, Horiike S . [Evaluation of clinical utility of 123I-MIBG scintigraphy in localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials]. Kaku Igaku. 2000; 37(1):43-59. View

10.

Ishii K . [Imaging diagnosis of dementia]. Nihon Rinsho. 2014; 72(4):681-6. View

11.

Nakajo M, Horizoe Y, Kawaji K, Jinguji M, Tani A, Fukukura Y . Application of I-MIBG myocardial maximum standardized uptake value to characterize cardiac function in patients with pheochromocytoma: comparison with echocardiography. Jpn J Radiol. 2022; 41(4):437-448. PMC: 10066163. DOI: 10.1007/s11604-022-01365-z. View

12.

Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T . Effect of Switching from Cilnidipine to Azelnidipine on Cardiac Sympathetic Nerve Function in Patients with Heart Failure Preserved Ejection Fraction. Int Heart J. 2017; 59(1):120-125. DOI: 10.1536/ihj.17-024. View

13.

Park J, Eggert A, Caron H . Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010; 24(1):65-86. DOI: 10.1016/j.hoc.2009.11.011. View

14.

Wieland D, Wu J, Brown L, Mangner T, Swanson D, BEIERWALTES W . Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980; 21(4):349-53. View

15.

Soman P, Travin M, Gerson M, Cullom S, Thompson R . I-123 MIBG Cardiac Imaging. J Nucl Cardiol. 2015; 22(4):677-85. DOI: 10.1007/s12350-015-0108-5. View

16.

Nakajima K, Matsumura T, Komatsu J, Wakabayashi H, Ono K, Kinuya S . Sympathetic I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging. Ann Nucl Med. 2024; 38(10):814-824. PMC: 11401792. DOI: 10.1007/s12149-024-01950-4. View

17.

Matthay K . Neuroblastoma: biology and therapy. Oncology (Williston Park). 1998; 11(12):1857-66; discussion 1869-72, 1875. View

18.

Taki J, Yoshita M, Yamada M, Tonami N . Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med. 2004; 18(6):453-61. DOI: 10.1007/BF02984560. View

19.

Homma K, Hayashi K, Wakino S, Irie R, Mukai M, Kumagai H . Primary malignant hepatic pheochromocytoma with negative adrenal scintigraphy. Hypertens Res. 2006; 29(7):551-4. DOI: 10.1291/hypres.29.551. View

20.

Kushner B, Yeh S, Kramer K, Larson S, Cheung N . Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol. 2003; 21(6):1082-6. DOI: 10.1200/JCO.2003.07.142. View